Q1 Earnings Estimate for VIGL Issued By William Blair

Vigil Neuroscience, Inc. (NASDAQ:VIGL) – Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Vigil Neuroscience in a research report issued on Thursday, March 13th. William Blair analyst S. Schram forecasts that the company will earn $0.49 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. William Blair also issued estimates for Vigil Neuroscience’s Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.57) EPS and FY2026 earnings at ($2.12) EPS.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08).

VIGL has been the subject of a number of other reports. HC Wainwright lowered their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday. Guggenheim reissued a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Wedbush decreased their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday. Finally, JMP Securities reissued a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Stock Down 4.3 %

VIGL opened at $2.02 on Monday. The business’s fifty day simple moving average is $2.34 and its 200 day simple moving average is $2.78. Vigil Neuroscience has a 52 week low of $1.49 and a 52 week high of $6.06. The stock has a market cap of $82.58 million, a PE ratio of -0.98 and a beta of 1.82.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. boosted its position in Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after purchasing an additional 115,000 shares during the last quarter. 683 Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 14.8% in the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock worth $2,380,000 after buying an additional 180,420 shares during the last quarter. Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock valued at $1,195,000 after buying an additional 97,580 shares during the period. abrdn plc increased its holdings in Vigil Neuroscience by 124.9% during the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the last quarter. Finally, Woodline Partners LP raised its position in Vigil Neuroscience by 239.1% in the fourth quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock worth $831,000 after acquiring an additional 344,614 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.